

Appendix B: Provincial Case Definitions for Diseases of Public Health Significance

**Disease: *Clostridium difficile* Infection (CDI) outbreaks
in public hospitals**

**[Known as *Clostridium difficile* associated disease
(CDAD) in the regulations under the HPPA]**

Effective: February 2019

***Clostridium difficile* Infection (CDI) outbreaks in public hospitals**

1.0 Provincial Reporting

Confirmed outbreaks and outbreak-associated cases occurring in hospitals under the *Public Hospitals Act*.

2.0 Type of Surveillance

Outbreak and case level data

3.0 Outbreak Classification

Clostridium difficile infection (CDI) outbreak definitions incorporate the concept of notification thresholds that optimally trigger action and dialogue between the local public health unit and the facility to determine if an outbreak is occurring.

Facilities should use the following CDI notification thresholds to assist them in determining the need for consultation with their local public health unit. Facilities with limited experience in managing CDI should consult with the local public health unit and/or with the local regional infection control network. These thresholds were developed by the Ministry of Health and Long-Term Care (the 'ministry').

3.1 Notification Thresholds are defined as:

For wards/units with ≥ 20 beds, three (3) new cases of nosocomial CDI identified on one ward/unit within a seven-day period OR five (5) new cases of nosocomial CDI within a four-week period,

OR

For wards/units with < 20 beds, two (2) new cases of nosocomial CDI identified on one ward/unit within a seven-day period OR four (4) new cases of nosocomial CDI within a four-week period,

OR

Facilities that have a facility nosocomial CDI rate that exceeds their annual nosocomial baseline rate for a period of two consecutive months. **Note:** This is not valid for a small community hospital, where a single case of nosocomial CDI can artificially elevate the facility rate.

It should be noted that exceeding a threshold does not necessarily imply that an outbreak will be declared. Following consultation between the facility and the local public health unit, decisions on the declaration of an outbreak will be made based on the following criteria:

- There has been a significant* (as determined by the facility and the local public health unit) increase in CDI numbers or rate compared to own baseline and/or that of comparator facilities.
- Recognized control measures are in place and are being used.
- There is epidemiologic evidence of ongoing nosocomial transmission on the ward/unit or facility.

3.2 Confirmed Case Definition

- Diarrhea[†] with laboratory confirmation of toxin A or B for *Clostridium difficile* (*C. difficile*) (e.g. Enzyme immunoassay (EIA) for toxin A or B, nucleic acid amplification testing (NAAT) for *C. difficile* toxin genes A or B, or *C. difficile* cytotoxicity assay);
OR
- Visualization of pseudomembranes on sigmoidoscopy or colonoscopy;
OR
- Histological/pathological diagnosis of pseudomembranous colitis;
OR
- Diagnosis of toxic megacolon.

For the purpose of defining a case of CDI, there should be three or more episodes of diarrhea within a 24-hour period.

The following definitions are from Ontario's mandatory patient safety reporting program and can be used to determine whether the case is nosocomial:

- **CDI Attributable to Your Facility**
 - The symptoms of CDI were not present on admission (i.e. onset of symptoms >72 hours after admission) or the infection is present at the time of admission but is related to a previous admission to your facility within the last four weeks.
- **CDI Not Attributable to Your Facility**
 - The symptoms of CDI were present on admission or <72 hours after admission and there was no admission to your facility within the last four weeks.
OR
 - The symptoms of CDI recur within two months of the last infection (relapse).

* Significance may be determined by reviewing:

- number of new nosocomial cases associated with the reporting ward/unit or facility
- historic level of CDI activity of the ward/unit or facility;
- current trend in ward/unit CDI activity or facility rate, and
- location of current cases and possible epidemiologic links between cases

[†] Diarrhea is defined as:

- loose/watery bowel movements (conform to the shape of the container), and
- the bowel movements are unusual or different for the patient, and
- there is no other recognized etiology for the diarrhea (for example, laxative use).

4.0 Laboratory Evidence

4.1 Laboratory Confirmation

Any of the following will constitute a confirmed case of CDI:

- Laboratory confirmation by validated methods
- Visualization of pseudomembranes on sigmoidoscopy or colonoscopy
- Histological/pathological diagnosis of pseudomembranous colitis
- Diagnosis of toxic megacolon

4.2 Approved/Validated Tests

- *C. difficile* enzyme immunoassay (EIA) for toxin (A and/or B)
- Molecular testing (NAAT) for *C. difficile* toxin genes (A and/or B)
- *C. difficile* cytotoxicity assay

4.3 Indications and Limitations

- Laboratory testing for CDI requires the identification of toxin A or B, or the genes related to cytotoxin production. Cultures for *C. difficile* are not routinely performed, and require confirmation of toxin A and/or B or the related genes.
- Stool specimen collection should occur as soon as possible after the onset of symptoms.
- Specimens are not recommended from patients who are less than 12 months old.
- Quick turnaround time for *C. difficile* testing is essential and should be pre-arranged with the microbiology laboratory serving the facility.
- A single negative EIA should not be relied on to rule out *C. difficile*. If a single EIA is negative, a second specimen should be sent.
- Testing by molecular methods such as PCR is more sensitive and if the first test is negative, a second test is not necessary. Some laboratories employ a two-step method, with detection of *C. difficile* glutamate dehydrogenase antigen (GDH) followed by a molecular test if GDH is positive. Molecular testing is now considered the testing method of choice.
- Testing can detect *C. difficile* colonization or disease. Results of laboratory testing must be correlated with the clinical condition of the patient. If the patient does not meet the case definition for CDI, he/she should not be counted as a case of CDI.
- *C. difficile* toxin testing is not recommended as a test of cure. Toxin and toxin genes may be detected long after clinical symptoms have resolved.
- Formed stool specimens will be rejected. If CDI is still suspected, contact the testing laboratory to arrange testing.

5.0 Clinical Evidence

Clinically compatible signs and symptoms are characterized by the following:

- Diarrhea (as defined above)
- Fever

- Loss of appetite
- Nausea and
- Abdominal pain or tenderness

C. difficile infection can lead to diseases ranging from mild diarrhea to toxic megacolon and death.

6.0 ICD 10 Code(s)

A04.7 Enterocolitis due to *Clostridium difficile*

7.0 Comments

- It should be noted that exceeding a threshold does not necessarily imply that an outbreak will be declared. Declaration of an outbreak can be made by either the institution or the Medical Officer of Health (MOH).
- In the event of a disagreement between the institution and the MOH, the MOH has the authority to determine if an outbreak of a communicable disease exists, for purposes of exercising statutory powers under the HPPA. Once an outbreak is declared it is reported to the Ministry through integrated Public Health Information System (iPHIS).
- The hospital may declare an outbreak over and shall consult with the MOH in doing so. Rationale for declaring or not declaring an outbreak, and declaring an outbreak over should be documented.

8.0 Sources

Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. *Annals of Surgery*. 2002;235(3):363.

Government of Canada. Fact Sheet - *Clostridium difficile* (*C. difficile*) [Internet]. 2014 [updated May 2, 2014. Available from: <https://www.canada.ca/en/public-health/services/infectious-diseases/fact-sheet-clostridium-difficile-difficile.html>

Ontario Agency for Health Protection and Promotion, Provincial Infectious Diseases Advisory Committee. *Annex C – Testing, Surveillance and Management of Clostridium difficile*. Annexed to: Routine Practices and Additional Precautions in All Health Care Settings. Toronto, ON: Queen's Printer for Ontario; 2013. Available from: https://www.publichealthontario.ca/en/BrowseByTopic/InfectiousDiseases/PIDAC/Pages/Routine_Practices_Additional_Precautions.aspx

Ontario Agency for Health Protection and Promotion (Public Health Ontario). Testing Information: *Clostridium difficile* [Internet]. Toronto, ON: Queen's Printer for Ontario; 2016 [updated September 30, 2016; cited June 11, 2018]. Available from: https://www.publichealthontario.ca/en/ServicesAndTools/LaboratoryServices/Pages/Clostridium_difficile_toxin_EIA.aspx

9.0 Document History

Table 1: History of Revisions

Revision Date	Document Section	Description of Revisions
January 2014	General	New template. Sections 9.0 Document History Added.
January 2014	3.0 Outbreak Classification	<p>Changed from “CDI outbreak definitions have been revised to incorporate the concept of notification thresholds, which are more sensitive than outbreak definitions” to “CDI outbreak definitions incorporate the concept of notification thresholds that optimally trigger action and dialogue between the local public health unit and the facility to determine if an outbreak is occurring.</p> <p>Facilities should use the following CDI notification thresholds to assist them in determining the need for consultation with their local public health unit.</p> <p>Facilities with limited experience in managing CDI should consult with the local public health unit and/or with the local regional infection control network. These thresholds were developed by the Ministry of Health and Long-Term Care (the ‘Ministry’).</p>

Revision Date	Document Section	Description of Revisions
January 2014	3.1 Notification Thresholds are defined as:	<p>First paragraph changed from "...3 cases of nosocomial CDI..." to "...three (3) new cases of nosocomial CDI..." and from "...5 cases within a..." to "...five (5) new cases of nosocomial CDI within a...".</p> <p>Second paragraph changed from "...2 cases of nosocomial CDI..." to "...two (2) new cases of nosocomial CDI..." and from "...or 4 cases within a 4 week period..." to "...four (4) new cases of nosocomial CDI within a four-week period...".</p> <p>Third paragraph changed from "Hospitals that have a baseline CDI rate for two months that is at or above the 80th percentile for comparator hospitals" to "Facilities that have a facility nosocomial CDI rate that exceeds their annual nosocomial baseline rate for a period of two consecutive months. NOTE: This is not valid for a small community hospital, where a single case of nosocomial CDI can artificially elevate the facility rate."</p> <p>"Hospitals that have a facility rate that is greater than or equal to 2 standard deviations above their baseline" deleted.</p> <p>"Hospitals that have a facility rate that is greater than or equal to 2 standard deviations above their baseline" added to the fourth paragraph.</p> <p>Second bullet point, "recognized control measures are in place and are being used" added to fourth paragraph.</p>

Revision Date	Document Section	Description of Revisions
January 2014	3.2 Confirmed Case Definition	PCR replace with nucleic acid amplification testing (NAAT) in first bullet point. “For the purpose of defining a case of CDI, there should be three or more episodes of diarrhea within a 24-hour period” added. Definitions to be used to determine whether the case is nosocomial revised.
January 2014	4.2 Approved/ Validated Tests	PCR replaced with NAAT in second bullet point.
January 2014	4.3 Indications and Limitations	Fourth bullet point changed from “Quick turnaround time for C. difficile cytotoxin and PCR testing is essential...” to “Quick turnaround time for C. difficile testing is essential...”. “The role of repeating a PCR test is not known, and is not routinely recommended” deleted from fifth bullet point. Sixth and seventh bullet points added.
January 2014	8.0 Sources	Updated.
February 2019	General	Minor revisions were made to support the regulation change to Diseases of Public Health Significance.
February 2019	6.0 ICD 10 Code(s)	Code updated.

